Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06595069 · ClinicalTrials.gov registry record
A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients
A clinical trial of Hypercholesterolemia, sponsored by Novartis.
- Completed
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT06595069: Completed study of Hypercholesterolemia, sponsored by Novartis.
NCT06595069 is a study of Hypercholesterolemia that has completed, run by Novartis. The registered enrollment target is 600 participants, below the 807-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (26% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06595069, a study of Hypercholesterolemia, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
This was a single-center, retrospective, observational study (non-interventional study with secondary use of data) among patients in a real-world setting. This study used the medical record data from patients in Yiling. Eligible patients who newly initiated inclisiran from 26 January 2022 to 21 August 2023 were included. The retrospective data up to the date of ethics committee approval (April 2024) was collected. The study team collected patient data using an electronic case report form (eCRF) from April 2024 to June 2024.
Conditions Studied
Study Locations (1)
New Jersey
- Novartis - East Hanover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2024-04-30 |
| Est. Completion | 2024-07-10 |
What the finished NCT06595069 record still lists
NCT06595069 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 807-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (26% lower).
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 0 interventions.
NCT06595069 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT06595069 about?
NCT06595069 is a clinical study titled "A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients". This was a single-center, retrospective, observational study (non-interventional study with secondary use of data) among patients in a real-world setting. This study used the medical record data from patients in Yiling. Eligible patients who newly initiated inclisiran from 26 January 2022 to 21 Aug...
What is the current status of trial NCT06595069?
This trial is currently completed. The enrollment target is 600 participants. The study started on 2024-04-30. Estimated completion is 2024-07-10.
What conditions does trial NCT06595069 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
Who is sponsoring clinical trial NCT06595069?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06595069 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06595069's enrollment target sits among peer trials
600 16th of 62 higher than 47 of 62 other Hypercholesterolemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypercholesterolemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pharmacokinetics of Butyrate Tablet BKR-017
RECRUITING
-
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
RECRUITING · Phase 2
-
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
RECRUITING · NA
-
Pharmacogenomic Informed Statin Prescribing
RECRUITING · NA
-
Causes and Natural History of Dyslipidemias
RECRUITING
-
A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI